53 related articles for article (PubMed ID: 27040669)
1. Effects of dipeptidyl peptidase-4 (DPP-4) inhibition on angiogenesis and hypoxic injury in type 2 diabetes.
Fiordaliso F; Maggioni S; Balconi G; Schiarea S; Corbelli A; De Luigi A; Figliuzzi M; Antoniou X; Chiabrando C; Masson S; Cervo L; Latini R
Life Sci; 2016 Jun; 154():87-95. PubMed ID: 27040669
[TBL] [Abstract][Full Text] [Related]
2. The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy.
Tsuprykov O; Ando R; Reichetzeder C; von Websky K; Antonenko V; Sharkovska Y; Chaykovska L; Rahnenführer J; Hasan AA; Tammen H; Alter M; Klein T; Ueda S; Yamagishi SI; Okuda S; Hocher B
Kidney Int; 2016 May; 89(5):1049-1061. PubMed ID: 27083282
[TBL] [Abstract][Full Text] [Related]
3. Effects of dipeptidyl peptidase-4 inhibitor in insulin-resistant rats with myocardial infarction.
Apaijai N; Inthachai T; Lekawanvijit S; Chattipakorn SC; Chattipakorn N
J Endocrinol; 2016 Jun; 229(3):245-58. PubMed ID: 27044778
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, safety and impact on β-cell function of dipeptidyl peptidase-4 inhibitors plus metformin combination therapy in patients with type 2 diabetes and the difference between Asians and Caucasians: a meta-analysis.
Gao W; Wang Q; Yu S
J Endocrinol Invest; 2016 Sep; 39(9):1061-74. PubMed ID: 27072669
[TBL] [Abstract][Full Text] [Related]
5. Glucagon-Like Peptide 1 Analogs and their Effects on Pancreatic Islets.
Tudurí E; López M; Diéguez C; Nadal A; Nogueiras R
Trends Endocrinol Metab; 2016 May; 27(5):304-318. PubMed ID: 27062006
[TBL] [Abstract][Full Text] [Related]
6. Suppression of connective tissue growth factor mediates the renoprotective effect of Sitagliptin rather than Pioglitazone in type 2 diabetes mellitus.
Ali SM; Khalifa H; Mostafa DK; El Sharkawy A
Life Sci; 2016 May; 153():180-7. PubMed ID: 27049870
[TBL] [Abstract][Full Text] [Related]
7. Effect of Dipeptidyl Peptidase-4 Inhibitors on Plasma Adiponectin: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Sahebkar A; Ponzo V; Bo S
Curr Med Chem; 2016; 23(13):1356-69. PubMed ID: 27048342
[TBL] [Abstract][Full Text] [Related]
8. Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial.
Tanaka A; Inoue T; Kitakaze M; Oyama J; Sata M; Taguchi I; Shimizu W; Watada H; Tomiyama H; Ako J; Sakata Y; Anzai T; Uematsu M; Suzuki M; Eguchi K; Yamashina A; Saito Y; Sato Y; Ueda S; Murohara T; Node K
Cardiovasc Diabetol; 2016 Apr; 15():57. PubMed ID: 27044332
[TBL] [Abstract][Full Text] [Related]
9. Risk of heart failure with dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
Kundu A; Sardar P; Ghosh S; Patel P; Chatterjee S; Meyer TE
Int J Cardiol; 2016 Jun; 212():203-5. PubMed ID: 27043061
[No Abstract] [Full Text] [Related]
10. Pleiotropic effects of sitagliptin versus voglibose in patients with type 2 diabetes inadequately controlled via diet and/or a single oral antihyperglycemic agent: a multicenter, randomized trial.
Matsushima Y; Takeshita Y; Kita Y; Otoda T; Kato K; Toyama-Wakakuri H; Akahori H; Shimizu A; Hamaguchi E; Nishimura Y; Kanamori T; Kaneko S; Takamura T
BMJ Open Diabetes Res Care; 2016; 4(1):e000190. PubMed ID: 27110370
[TBL] [Abstract][Full Text] [Related]
11. Outcome studies and safety as guide for decision making in treating patients with type 2 diabetes.
Cahn A; Cernea S; Raz I
Rev Endocr Metab Disord; 2016 Mar; 17(1):117-27. PubMed ID: 27106831
[TBL] [Abstract][Full Text] [Related]
12. Plasma Incretin Levels and Dipeptidyl Peptidase-4 Activity in Patients with Obstructive Sleep Apnea.
Matsumoto T; Harada N; Azuma M; Chihara Y; Murase K; Tachikawa R; Minami T; Hamada S; Tanizawa K; Inouchi M; Oga T; Mishima M; Chin K
Ann Am Thorac Soc; 2016 Aug; 13(8):1378-87. PubMed ID: 27104640
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Canagliflozin in Type 2 Diabetes Patients of Different Ethnicity.
Davidson JA; Aguilar R; Lavalle González FJ; Trujillo A; Alba M; Vijapurkar U; Meininger G
Ethn Dis; 2016 Apr; 26(2):221-8. PubMed ID: 27103773
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program.
Jendle J; Grunberger G; Blevins T; Giorgino F; Hietpas RT; Botros FT
Diabetes Metab Res Rev; 2016 Nov; 32(8):776-790. PubMed ID: 27102969
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin.
Kim JH; Kim SS; Baek HS; Lee IK; Chung DJ; Sohn HS; Bae HY; Kim MK; Park JH; Choi YS; Kim YI; Hahm JR; Lee CW; Jo SR; Park MK; Lee KJ; Kim IJ
Diabetes Metab J; 2016 Jun; 40(3):230-9. PubMed ID: 27098505
[TBL] [Abstract][Full Text] [Related]
16. Euglycemic Diabetic Ketoacidosis: A Review.
Modi A; Agrawal A; Morgan F
Curr Diabetes Rev; 2017; 13(3):315-321. PubMed ID: 27097605
[TBL] [Abstract][Full Text] [Related]
17. Factors Influencing Changes in Hemoglobin A1c and Body Weight During Treatment of Type 2 Diabetes With Ipragliflozin: Interim Analysis of the ASSIGN-K Study.
Iemitsu K; Iizuka T; Takihata M; Takai M; Nakajima S; Minami N; Umezawa S; Kanamori A; Takeda H; Kawata T; Ito S; Kikuchi T; Amemiya H; Kaneshiro M; Mokubo A; Takuma T; Machimura H; Tanaka K; Asakura T; Kubota A; Aoyagi S; Hoshino K; Ishikawa M; Obana M; Sasai N; Kaneshige H; Miyakawa M; Tanaka Y; Terauchi Y; Matsuba I
J Clin Med Res; 2016 May; 8(5):373-8. PubMed ID: 27081422
[TBL] [Abstract][Full Text] [Related]
18. Glucose-independent renoprotective mechanisms of the tissue dipeptidyl peptidase-4 inhibitor, saxagliptin, in Dahl salt-sensitive hypertensive rats.
Uchii M; Kimoto N; Sakai M; Kitayama T; Kunori S
Eur J Pharmacol; 2016 Jul; 783():56-63. PubMed ID: 27063445
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial.
Zang L; Liu Y; Geng J; Luo Y; Bian F; Lv X; Yang J; Liu J; Peng Y; Li Y; Sun Y; Bosch-Traberg H; Mu Y
Diabetes Obes Metab; 2016 Aug; 18(8):803-11. PubMed ID: 27060930
[TBL] [Abstract][Full Text] [Related]
20. Generalized Intense Pruritus During Canagliflozin Treatment: Is it an Adverse Drug Reaction?
Vasapollo P; Cione E; Luciani F; Gallelli L
Curr Drug Saf; 2018; 13(1):38-40. PubMed ID: 27048192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
